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Abstract
The equine sarcoid is the most common skin neoplasia in the horse. It has a 
worldwide distribution and can also affect other equids such as donkeys, zebras, 
and mules. All breeds can develop the disease at any age, with no sex predilection, 
although geldings seem to be overrepresented. This fibroblastic neoplasm has 
several clinical presentations and microscopic features and has a nonmetastatic 
behavior but can be severely locally invasive. In many cases, multiple sarcoids may 
develop simultaneously or sequentially during their life and spontaneous remission 
is rarely reported. The etiology is multifactorial and involves bovine papilloma-
viruses, genetic, and environmental factors. Treatment options include different 
modalities depending on multiple factors: lesion type, location and extent, indi-
vidual patient, facilities, owner, and financial issues.
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1. Introduction
The equine sarcoid is the most common skin neoplasia in the horse. This fibro-
blastic neoplasm has a multifactorial etiology and is nonmetastatic but can be 
severely locally invasive. First described in 1936, it has a worldwide distribution 
and can also affect other equids such as donkeys, zebras, and mules as well as other 
 mammals [1–3]. Prevalence of sarcoid varies among published studies; however, 
many reports include cases from referral clinics that may not exactly reflect the 
entire equine population. Reported percentages of sarcoid among skin diseases and 
skin neoplasms vary from 13% to 90% and 8% to 38% when considering ocular neo-
plasms. There are also some geographical variations that may correlate with varia-
tions of risk factors, including the presence of cattle and vectors near horses [1, 4–6]. 
Horses of all breeds and colors can develop the disease at any age, most presenting a 
first lesion between 2 and 9 years of age. There is no demonstrated sex predilection, 
although geldings seem to be overrepresented [3, 5, 7]. Data about the incidence of 
sarcoids in the population are available only for donkeys and not for horses [8].
Affected animals can never be considered free of the disease even after success-
ful treatment and presence or history of sarcoid can lower the likely sale value of 
the animal [2].
2. Etiopathogenesis of the equine sarcoid
2.1 Bovine papillomavirus infection
To date, it is widely recognized that sarcoids are associated with the presence 
of bovine papillomaviruses (BPV), typically BPV-1 and/or BPV-2. In two Brazilian 
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studies, newly proposed BPV ‘BsR-UEL-4’ and BPV-13 were found in some equine 
sarcoids, suggesting the need for further research regarding BPV serotype involve-
ment in the development of these tumors [9–12].
The prevalence of BPV-1 and BPV-2 types seem to vary among geographical 
areas. In Europe and Australia, BPV-1 is most detected. In eastern USA, an almost 
equal proportion of both virus types was found, whereas in Canada and Western 
USA, BPV-2 was demonstrated in most of the samples [12–17].
The bovine papillomavirus genome comprises early and late coding regions. The 
early (E) genes encode nonstructural proteins involved in viral replication, mainte-
nance of the episomal state, and activation of cell proliferation. The late (L) genes 
encode structural proteins (viral capsid) produced only in the life cycle of keratino-
cytes in natural hosts. A non-coding long control region is also present playing a role 
in viral replication and transcription [18, 19]. The main factors identified in sarcoid 
oncogenesis are the E2, E5, E6, E7, and p53 proteins. The E2 protein has regulatory 
effects on viral transcription and on the expression of matrix metalloproteinases 
(MMPs) that may be implicated in neoplastic cell invasiveness. The E5 protein exerts 
its function by binding to platelet-derived growth factor-β receptor (PDGFβ-R) 
thus activating p38 mitogen-activated protein kinase (MAPK) to induce fibroblastic 
transformation in sarcoids and down-regulate the major histocompatibility complex 
(MHC) I to facilitate the evasion of the immune system. The E6 protein can interfere 
in the activity of the p53 protein and has anti-apoptotic activity. The E7 protein 
cooperates in evading innate immunity [19–27]. The oncogenesis of equine sarcoids 
also involves loss of expression of the Fragile Histidine Triad (FHIT) and of the 
O6-methylguanine-DNA methyltransferase (MGMT) tumor suppressor proteins 
[28, 29]. Recent studies have evaluated the role of small non-coding RNAs that 
regulate gene expression (microRNAs) in the development of sarcoids, and the role 
of aberrant methylation (S100A14 gene) is under research [30–34].
It seems that BPV infection in horses starts in the epidermis, where it can remain 
latent, with a subsequent presence of viral material within sub-epidermal fibroblasts 
where full transformation takes place [35–37]. Latency seems to take place also in 
peripheral blood mononuclear cells (PBMC) [38]. The infection in horses is abor-
tive, the virus is present episomally but intact virions have never been detected. 
Furthermore, intralesional viral load seems to be correlated to disease severity [39, 40].
2.2 BPV transmission
Viral transmission between animals has not been completely elucidated yet. 
Direct contact with cattle, contaminated surfaces, and flies are presumably the 
most common routes of transmission [35, 36, 41, 42]. Infected equids may pos-
sibly spread BPV infection to horses and donkeys through contact. Appropriate fly 
protection and hygiene should be basic control measures in the presence of cattle 
and sarcoid-affected animals [35, 36].
2.3 Genetic risk factors
Bovine papillomavirus infection alone is not sufficient to promote normal 
cells transformation into sarcoid tumors, the presence of genetic factors and 
trauma are associated with the disease [43]. All breeds can be affected but Quarter 
Horses, Appaloosas, and Arabian horses are reported to be at greater risk than 
Thoroughbreds. Standardbreds have an even lower risk of developing sarcoids  
[5, 44, 45]. Certain equine families have an increased prevalence of sarcoid lesions 
and an association between the disease and equine leukocyte antigen (ELA) alleles 
has been observed in several breeds. The ELA W13 allele associated with the MHC 
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II has been linked with sarcoid susceptibility in studies involving different breeds 
such as Swiss, Irish, French, and Swedish Warmbloods, and Thoroughbreds. The 
ELA W13 allele is not expressed in Standardbreds, a breed at lower risk of develop-
ing lesions [43, 46, 47]. Other MCH-encoded antigens are reported to play a role in 
sarcoid development: W3, B1, A3, A5, A16, A20, W5, W11, and W21 [1, 48–50]. A 
breed specific antigen, the Abe108, has been associated with sarcoids in Freiberger 
horses that lack A3, A5, and W13 antigens [50].
2.4 Trauma
Skin trauma is involved in sarcoid initiation, progression, and possibly recur-
rence. Micro-trauma due to injections (Figure 1) or even insect bites can be fol-
lowed by sarcoid development, even long after apparent healing. Furthermore, 
sarcoids are a well-recognized possible complication and cause for delayed healing 
in both traumatic and surgical wounds in horses [2, 5, 51].
3. The biological behavior of the equine sarcoid
An individual animal may present only with one sarcoid, but most commonly, 
affected horses develop multiple sarcoids during their lives. These neoplasms may 
remain static for months or years and then, slowly or suddenly become aggressive 
and progress in type and/or extension without apparent reason (Figure 2A and B). 
Sarcoids tend to be locally invasive, sometimes extending into subcutaneous and 
Figure 1. 
Sarcoid development on the jugular groove, possibly triggered by injection micro-trauma.
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muscular planes, especially periocular lesions. They do not metastasize, however, 
with the exception of the malignant form that can spread to lymphatics and cause 
the formation of multiple masses along the lymphatic vessels and at remote sites 
such as lymph nodes [52].
Spontaneous regression is rarely reported and usually these horses do not 
develop new sarcoid tumors. Only in one recent study on a population of Franches-
Montagnes horses in Switzerland has a high proportion of spontaneous remission 
been observed [53]. The mechanisms for spontaneous regression are not clear and 
antibodies have been detected only in donkeys [5].
The equine sarcoid has high frequency of recurrence after treatment (Figure 2C), 
especially following surgical excision. Recurrent tumors are usually more aggressive 
than the initial lesion and tend to grow rapidly and be more invasive. Recurring 
sarcoids can appear within a few days or weeks to months or years. The recur-
rence is often due to incomplete removal or spread of sarcoid cells during the 
procedure [1, 2, 52].
Figure 2. 
(A) Ear sarcoid slowly grown over years. (B) Same horse (hair clipped) few weeks after, the sarcoid underwent 
rapid growth at the beginning of the fly season. (C) Fibroblastic sarcoid development on a recently treated 
occult sarcoid. Note the “healthy” scar on the right where a similar occult sarcoid was successfully treated 
simultaneously.
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4. Clinical presentations of the equine sarcoid
Sarcoids have been classified into six different types depending on their mac-
roscopic appearance (Table 1). This clinical classification is important because 
different types require different therapeutic approaches and have differing prog-
noses. One subject may carry more than one type of sarcoid and commonly, though 
unpredictably, milder forms can progress to more severe types [52, 54, 55].
4.1 Occult sarcoid
The occult sarcoid presents as an area of hairless skin, generally roughly circular. 
The skin may be thinned and/or have variably hyperkeratotic or roughened areas 
and contain one or more nodules, usually about 2–5 mm in diameter (Figure 3A 
and B). Occult sarcoids may involve extensive surfaces and individual horses may 
carry several lesions (Figure 3C). In some cases, only partial alopecia with thin 
hair and mild changes in skin and/or hair pigmentation (darker or paler) can be 
detected. Pruritus and pain are not present. These sarcoids have a slow progression 
toward verrucose growth.
Occult lesions can develop at any site but with predilection for the skin around 
mouth, eyes, the neck, and areas with less hair such as the medial thighs (Figure 3D) 
and forearms. They rarely affect the limbs.
Differential diagnoses for occult sarcoids are: idiopathic hypotrichosis/alopecia, 
dermatophytosis, alopecia areata, rub marks, chronic rubbing and scarring, bullous 
conditions (pemphigus foliaceous, and vasculitis), and burns.
Type Subtype Features
Occult — Roughly circular, hairless thinned and/or hyperkeratotic skin, 
may contain nodules
Verrucose — Warty, hyperkeratotic area, may have nodules and/or occult halo
Nodular Subcutaneous spherical masses
A—no cutaneous 
involvement
A1 Deeper tissues are not involved, loose capsule and defined 
margins
A2 Deep tissue involvement with poorly defined margins and 
invasive ‘bound-down’ nature
B—cutaneous 
involvement
B1 Deeper tissues are not involved, loose capsule and defined 
margins
B2 Deep tissue involvement with poorly defined margins and 
invasive ‘bound-down’ nature
Fibroblastic Fleshy, ulcerated appearance, fibrocelullar scab
1—pedunculated 1a Distinct pedicle without palpable or histological presence of 
tumor extensions
1b Distinct pedicle with palpable root, poorly defined margins, 
invasive ‘bound-down’ nature
2—sessile/broad-based Poorly defined margins, invasive ‘bound-down’
Mixed — Verrucose, nodular and fibroblastic features present in variable 
proportions within the same lesion
Malignant — Multiple, locally invasive nodular and fibroblastic sarcoids with 
subcutaneous connections, may spread to lymphatics
Table 1. 
Summary of the clinical classification of sarcoid types and features.
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4.2 Verrucose sarcoid
The verrucose form has a characteristic “wart-like” appearance, which is the 
main reason for calling sarcoids “warts”. These lesions are alopecic and neither 
pruritic nor painful unless secondarily infected (Figure 4A). Some may ulcerate 
and bleed (Figure 4B). Thickness and size vary, small nodules may develop in the 
hyperkeratotic area and some lesions may present a pathognomonic occult margin/
halo (Figure 4C). They usually grow slowly but progression to a more aggressive 
form is possible, especially with trauma. As occult sarcoids, the verrucose ones can 
coalesce and cover large body areas (Figure 5).
Verrucose sarcoids can develop in any region with predilection sites being face 
(periorbital), axillae, groin, body, and sheath. Limbs are rarely affected.
Differential diagnoses for verrucose sarcoids are: papillomatosis (warts), linear 
keratosis/epidermal nevus, dermatophytosis, chronic blistering.
4.3 Nodular sarcoid
Nodular sarcoids are firm and well-defined subcutaneous masses, usually 
spherical with variable diameters from few mm to 7 cm. In many cases, the nod-
ules may be multiple and coalescing. Pain and pruritus are not typical features. 
Figure 3. 
(A) Occult sarcoid in the pectoral region: circular roughened hairless area with one small nodule within. 
(B) Large occult sarcoid: note mild hair loss, alterations in skin pigmentation, and presence of nodules. 
(C) Multiple occult sarcoids, the central one has a verrucose central area with occult halo. (D) Early occult 
sarcoid (blue circle) on the medial thigh. Sparsely haired shining skin with mild pigmentary changes.
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Figure 4. 
(A) Verrucose sarcoid in the axillary region (hair has been clipped), note another one in the sternal region. 
(B) Verrucose sarcoid with fissures and mild bleeding. (C) Verrucose sarcoid with occult halo.
Figure 5. 
(A) Large verrucose sarcoid with nodular formations on the side of the neck. (B) Same horse after hair 
clipping: note extended hyperkeratotic and occult areas that were not previously visible because of  
coverage by hair.
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Similar to other forms, they very rarely develop on the limbs and the predilection 
sites are the groin, sheath, and eyelids.
A further classification has been suggested for these sarcoids based on skin and 
deep tissues involvement.
• Type A nodules do not involve skin that is not altered and can be freely moved 
over the nodule. Two subtypes exist:
 ○ Type A1: the nodule can be moved from both the skin and the underlying 
tissues, usually has a fibrocelullar capsule. In some lesions, a skin pedicle is 
palpable.
 ○ Type A2: no skin involvement but the nodule cannot be moved indepen-
dently from the underlying tissues, it has a ‘bound-down’ nature. Very 
common around the eye.
• Type B nodules are characterized by visible and/or palpable alterations of 
the skin. They cannot be freely moved from the overlying skin that may look 
normal or be alopecic, thinned, hyperkeratotic, or ulcerated. Some may have 
adjacent occult changes. Also, two subtypes are recognized:
 ○ Type B1: no involvement of the deeper structures (Figure 6A).
 ○ Type B2: locally invasive with ‘bound-down’ nature and no separation from 
deeper layers (Figure 6B).
Differential diagnoses for nodular sarcoids are: fibroma/fibrosarcoma, neu-
rofibroma, eosinophilic/collagenolytic granuloma, melanoma, equine cutane-
ous mastocytosis/malignant cutaneous mastocytosis/congenital mastocytoma, 
lymphosarcoma/lymphoma/cutaneous histiocytic lymphoma, dermoid cyst, and 
Hypoderma spp./foreign body cyst.
4.4 Fibroblastic sarcoid
Fibroblastic sarcoids are a more aggressive form with fleshy and ulcerated 
appearance, often covered by a fibrocellular scab and possibly secondary infection. 
Figure 6. 
(A) Type B1 nodular sarcoid on the medial thigh. (B) Three type B2 nodular sarcoids around the eye, an occult 
area is also present.
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Bleeding  and serum exudation are common and can be heavy with trauma. These 
surface characteristics attract flies that may contribute to irritation and self-trauma. 
Fibroblastic sarcoids commonly develop at wound sites (both traumatic and 
surgical), on the site of other sarcoids, especially if treatment attempts have been 
unsuccessful (Figure 2C) and they are usually more difficult to manage. Excessive 
granulation tissue may develop especially at wound sites thus complicating the diag-
nosis of sarcoid. Pruritus and pain rarely characterize these lesions. Predilection sites 
for fibroblastic sarcoids are groin, eyelid, wounds, coronets, and distal limbs. At some 
of these sites they carry a very poor prognosis. The classification of this form includes:
• Type 1 pedunculated fibroblastic sarcoids: characterized by a narrow pedicle 
with apparently normal skin and a fleshy crown. Subtypes are:
 ○ Type 1a: pedunculated with no palpable tumor and thickening at the base, 
no extensions detected on histology (Figure 7A).
 ○ Type 1b: this is pedunculated and rooted, where palpable alterations 
are detected beneath the pedicle, sometimes alteration are also visible 
(Figure 7B).
• Type 2 sessile fibroblastic sarcoid: the lesion is broad-based with invariably 
ill-defined margins and extensive invasion of the lateral and deeper  
tissues (Figure 7C).
Differential diagnoses for fibroblastic sarcoids are: exuberant granulation 
tissue, habronemiasis, pythiosis, botryomycosis/pyogranuloma/pseudomycetoma, 
Figure 7. 
(A) Type 1a fibroblastic sarcoid on the penis. (B) Type 1b fibroblastic sarcoid with clear tumor involvement of 
the pedicle. (C) Type 2 sessile fibroblastic sarcoid.
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hemangioma/hemangiosarcoma, cavernous hemangioma/vascular hamartoma, 
neurofibroma/neurofibrosarcoma (ulcerated), fibrosarcoma, squamous cell carci-
noma, sweat gland tumor, giant cell sarcoma, and mycosis fungoides.
4.5 Mixed sarcoid
Most sarcoids could be classified as mixed since different types (verrucose, 
nodular, and fibroblastic) are often present in variable proportions within the 
same lesion. Nevertheless, the definition of mixed sarcoid is usually reserved for 
those where a specific sarcoid type is not considered predominant. These cases 
may probably represent the transition/progression phase between one clinical type 
into the other. The combinations and extents of the various types are multiple, and 
they usually tend to become more aggressive, especially as the fibroblastic type 
grows (Figure 8).
Predilection sites for mixed sarcoids are the face, eyelids, groin, and medial 
thigh but mixed sarcoids can appear everywhere.
Differential diagnoses for mixed sarcoids are mixtures of granulation tissue 
within verrucose or fibroblastic lesions, habronemiasis, pemphigus complex.
4.6 Malignant sarcoid
The most recently described form of sarcoid tumor is the malignant type. It is 
usually, but not always, characterized by a history of repeated trauma or inter-
ference (also with inappropriate treatments) with another type of sarcoid. The 
particular behavior of the malignant type is the development of multiple, locally 
invasive nodular and fibroblastic sarcoids. Often cords of nodules and ulcerated 
lesions are visible and/or palpable, when these connections are subcutaneous 
the classification should be that of malignant sarcoid. They can be localized or 
spread through the lymphatic vessels invading local tissues with possible associ-
ated lymph node enlargement. No disseminated metastasis has been reported 
even for this form. A rare particular and dangerous form presents with a ring of 
nodules surrounding a verrucose or occult central area, especially on the neck/
jugular and buttock regions. Predilection sites include jaw, face (Figure 9), 
elbow, and medial thigh.
Differential diagnoses for malignant sarcoids are squamous cell carcinoma, 
 lymphoma/lymphosarcoma, subcutaneous mycosis, lymphangitis, glanders, 
 epizootic lymphangitis/histoplasmosis, and hypertrophic scarring/cheloid.
Figure 8. 
Mixed sarcoid: a type B2 nodule with a small fibroblastic sarcoid within an occult area.
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5. Clinical examination and diagnostic procedures
The clinical examination should include signalment and a full thorough history 
with details on lesion development, especially about the behavior and progression. 
The clinical presentation of sarcoid lesions and their features are usually clearly rec-
ognizable, especially if multiple tumors of different types are present on the same 
horse. The confirmation of the diagnosis is not always straightforward and possible 
differential diagnoses and concurrent conditions should be considered [55, 56].
Depending on the sarcoid type, the full list of differential diagnoses should be 
considered when choosing the diagnostic procedures. The diagnosis of sarcoid is 
confirmed by histopathology, thus a biopsy sample is needed. Partial or excisional 
biopsy should provide sufficient information but a risk of exacerbation due to the 
surgical trauma should always be taken into account. If possible, a total excisional 
biopsy is preferable, the owner should be carefully advised about the implicit risks 
and a proper therapeutic plan should be prepared when taking the biopsy to avoid 
any exacerbation triggered by the procedure. If benign neglect is the plan, the 
opportunity of taking a biopsy should be carefully evaluated [2, 55].
5.1 Equine sarcoid pathology
Histopathology is deemed necessary to confirm the diagnosis of many equine 
sarcoids [57]. It is important to stress that due to the variable microscopic features 
of equine sarcoids, small biopsies may not provide enough tissue to differentiate 
sarcoids from other lesions such as granulation tissue, fibromas, or fibrosarcomas. 
Figure 9. 
Malignant sarcoid on the face: ‘bound-down’ invasive nodules with a central area with occult to verrucose 
changes, ulceration, and a fibroblastic component.
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This is especially true if samples are obtained from ulcerated areas of the tumors 
[58]. Notably, trauma and reparative processes (wound healing) may activate 
cell growth and facilitate the development or heighten the progression of equine 
sarcoids [57–59], particularly for verrucose, occult and small nodular sarcoids 
[60]. Thus, excisional biopsies with wide margins should be favored for clinical 
reasons and because they provide with the most diagnostic material [46, 58]. If a 
 non-excisional biopsy must be performed, sites within the mass must be carefully 
chosen to minimize the confounding factors of surrounding inflammation and 
granulation and to include intact epidermis [46].
Sarcoids derive from the proliferation of two components: the dermal fibroblasts 
and epidermal keratinocytes. They are regarded as biphasic tumors. Histopathology 
is heterogeneous and microscopic aspects and number of components varies 
according to the type of sarcoid [61].
Microscopic features of the epidermis may include orthokeratotic to compact 
hyperkeratosis, parakeratosis, irregular hyperplasia with epithelial proliferations 
producing long and pointed branches, termed rete pegs or rete ridges, extending 
deep into the dermal proliferation (Figure 10A) [46]. Epidermal ulceration is vari-
able but frequent in nodular and fibroblastic sarcoids.
The amount of epithelial cell proliferation varies according with the type of 
sarcoid and ranges from severe hyperplasia to epidermal atrophy [1, 61]. Overall 
up to 46% of sarcoids lack epidermal hyperplasia and 54% lack rete peg formation 
[61]. Epidermal changes are maximal in verrucous sarcoids [58] and can be minimal 
to absent in nodular and occult sarcoids. Epidermal ulceration is common especially 
in nodular sarcoids [58].
All sarcoids are characterized by variable substitution of normal dermal 
components by neoplastic fibroblasts embedded in variable amounts of collagen. 
Histopathological findings consist of poorly demarcated, unencapsulated, variably 
infiltrative proliferation of large spindle to stellate, bland to highly atypical fibro-
blasts with plump, oval, nuclei with granular chromatin and variable hyperchroma-
sia and with prominent nucleoli. Cellular atypia is low to absent and increases with 
time, number of excisions, ulceration, inflammation and type of sarcoid, being 
higher in malignant and mixed sarcoids. Number of mitoses is generally low (0–1 
per HPF) if excluding malignant sarcoids. Density of neoplastic fibroblast is often-
times higher in the superficial dermis [61]. At the dermal-epidermal junction, fibro-
blasts may be oriented perpendicularly to the basement membrane in the so-called 
“picket fence” arrangement (Figure 10B and C) [61–63]. This feature is considered 
highly diagnostic but is missing in up to 52% of sarcoids [61]. Additional patterns 
that can been seen at all levels of the dermis are whorling (Figure 11A), present in 
over 86% of tumors [64], parallel to interlacing short bundles (Figure 11B), stori-
form, herringbone, tangles or fibroblasts may be haphazardly arranged, this latter 
arrangement occurring more often in flat sarcoids (Figure 11C) [46, 62]. Amount 
of collagen matrix varies from minimal to abundant and can be dense, edematous, 
or myxoid (Figure 11D). Adnexal structures are variably reduced in density or 
obscured by the neoplasm [46].
Of all types of equine sarcoids, flat/occult sarcoids at initial stages can be easily 
overlooked at histopathology [63]. For this type of sarcoid, the only histopathologic 
finding may be an increased density of subepidermal neoplastic fibroblasts infiltrat-
ing between a reduced number of hair follicles and sweat glands [61]. The density of 
dermal fibroblasts is lower compared with the other types of sarcoids [58].
Immunohistochemistry can assist in the diagnosis of sarcoids although protein 
expression patterns are not considered highly specific. Fibroblasts in sarcoid 
express vimentin, the intermediate filament identifying mesodermal origin, 
and may be variably positive for laminin, smooth muscle actin, and type IV 
13
Equine Sarcoid
DOI: http://dx.doi.org/10.5772/intechopen.91013
collagen [59, 65, 66]. Sarcoids are generally S100 negative [65], however, S100 
focal expression has been observed [66]. Bovine papillomavirus is involved in the 
pathogenesis of equine sarcoids, however, BPV infection of fibroblasts is mainly 
nonproductive [10]. Therefore immunohistochemistry against BPV is mostly 
negative [62].
BPV DNA can be detected by in situ hybridization and PCR on formalin fixed 
and paraffin embedded tissue sections of biopsy samples [36, 65, 67] or by PCR fresh 
cytological specimens obtained by swabbing or scraping of equine sarcoid tissue in 
non-healing wounds and recurrent cases and following recurrence after surgery [9]. 
Figure 10. 
(A) Moderate hyperkeratosis and severe epidermal irregular hyperplasia with rete peg formation. In the 
superficial dermis higher density of neoplastic fibroblasts compared to mid dermis is evident. Hematoxylin 
and eosin, 200×. (B) Moderate compact hyperkeratosis with mild epidermal hyperplasia and mild rete peg 
formation. In the superficial and mid dermis, typical picket fence arrangement of fibroblasts is present. The 
picket fence pattern is considered a highly diagnostic pattern but is observed in less than 50% of equine sarcoids. 
Hematoxylin and eosin, 20×. (C) Moderate compact hyperkeratosis with mild epidermal hyperplasia and rete 
peg formation. In the superficial dermis, high cellularity and typical picket fence arrangement of fibroblasts 
are present. The picket fence pattern is considered a highly diagnostic pattern but is observed in less than 50% 
of equine sarcoids. Hematoxylin and eosin, 100×.
Equine Science
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DNA from BPV 1, 2 [14, 67] and 13 [12] is detected in up to 90% of equine sarcoids 
by in situ hybridization in the nuclei of fibroblasts and keratinocytes [37, 67]. 
Disadvantages of DNA detection are the unsuitability for diagnosing occult sarcoids, 
the lower sensitivity compared to clinical diagnosis, and the low specificity due to 
high prevalence of BPV DNA positivity in normal equine skin samples [35], cutane-
ous inflammation [68], and in other skin-associated spindle cell soft tissue tumors 
such as peripheral nerve sheath tumors (PNSTs), fibrosarcomas, myxosarcomas, 
and fibromas [66].
In summary, the most diagnostic histopathologic features, when present, are 
the epidermal changes of hyperkeratosis, hyperplasia with elongated rete pegs 
and “picket fence” aspect in conjunction by proliferation of fibroblasts [9, 35, 62]. 
However, common to most sarcoids are the fibroblastic dermal proliferation and 
presence of BPV DNA [10, 35, 67].
Microscopic features of sarcoids can overlap with other lesions. Differential diagno-
sis may be challenging because of the variable histological configuration of the dermal 
proliferation especially in cases with extensive ulceration or lack of distinctive epider-
mal lesions. Major histopathological differentials include granulation tissue (proud 
flesh), fibroma, fibrosarcoma, and peripheral nerve sheath tumors (e.g. schwannoma 
and neurofibroma) [57, 63]. Granulation tissue is characterized by fibrous tissue 
oriented at right angles to newly formed capillaries and is often associated with edema 
Figure 11. 
(A) Bland neoplastic fibroblasts whorling around a thick collagen bundle. Whorling is considered a highly 
diagnostic pattern described in over 85% of equine sarcoids. Hematoxylin and eosin, 200×. (B) Area of high 
cellularity with plump neoplastic fibroblasts embedded in finely fibrillar to dense collagen and organized in 
parallel and perpendicular rows. Moderate anisocytosis and anisokaryosis are evident. Hematoxylin and eosin, 
400×. (C) Area of moderate cellularity with parallel to haphazardly arranged plump fibroblasts embedded in 
abundant finely fibrillar to dense collagen. Moderate anisokaryosis is evident. Hematoxylin and eosin, 400×. 
(D) Area of high cellularity with haphazardly arranged highly atypical fibroblasts with spindle to stellate 
morphology embedded in finely fibrillar to myxoid stroma observed in a recurrent sarcoid. Hematoxylin and 
eosin, 200×.
15
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and a prominent inflammatory component. When fibroblastic sarcoids are ulcer-
ated, it may not be possible to differentiate them from granulation tissue and clinical 
follow-up becomes necessary. Fibromas can be differentiated morphologically as 
 well-circumscribed, expansile, sparsely cellular tumors composed of a monomorphic 
population of mature fibroblasts with no epidermal proliferation. Fibrosarcoma is 
more pleomorphic with higher cytological atypia but multiple patterns are rarely 
observed, and the epidermal component is absent. Peripheral nerve sheath tumors 
(PNST)/Schwannoma are characterized by variable presence of highly cellular often 
palisading areas (Antoni A pattern) and low cellular myxoid areas (Antoni B pattern). 
These areas are associated with the presence of typical Verocay bodies composed of 
acellular areas between areas of nuclear palisading. Immunohistochemical staining for 
S-100 protein may be useful in differentiating PNSTs from sarcoids; however, focal 
S100 positivity has been reported in sarcoids [62, 66].
6. Management of the equine sarcoid
A treatment should be prompted as soon as possible following diagnosis, and in 
some cases, suspicious lesions could be treated immediately after biopsy [5].
Several treatment modalities for the management of equine sarcoids are his-
torically ‘known’ and anecdotal reports and retrospective studies on more or less 
effective therapies exist, but valuable prospective double-blinded trials are lacking 
in the literature [3].
6.1 General considerations
Before choosing a proper therapeutic plan, some general considerations must be 
made [3, 55]:
• The prognosis is usually very guarded and owners must be thoroughly 
informed about possible complications associated with the condition.
• Sarcoid-affected animals can never be considered free of the disease, even after 
successful treatment.
• Each lesion can require a specific treatment and can react in a different way 
compared to other sarcoids even on the same horse.
• The extent and location of the tumor greatly affect the decisional process. 
Periorbital sarcoids (Figure 12) tend to penetrate the underlying musculature. 
Function of the upper eyelid must be preserved and any possible deformation 
in the healing process must be avoided. Sarcoids over tendons, joints or the 
facial nerve can have severe complications. The worst sites are the elbow and 
the face, where sarcoids much more tend to local invasion and progression to 
the malignant form.
• The duration of the lesion is important as early intervention usually requires 
less aggressive treatments. It is also easier to treat small lesions that extensive 
ones that may also be under transformation from one type to the other.
• Previous therapies and/or interferences influence the response to a new 
treatment course and possibly a different approach may be indicated. 
Equine Science
16
Wrong interference is a major cause of exacerbation and the prognosis signifi-
cantly reduces with each treatment failure.
• Planning combined, prolonged or repeated treatments can be necessary for 
many sarcoids.
• Costs and logistics can have a great influence on the choice of the therapeutic 
modality.
• Professional skills and experience of the veterinarian can also affect the rate 
of success and the same treatment used by different clinicians can result in 
different outcomes.
• Animal and owner compliance for the best treatment: some are very painful, 
some sites (e.g. ear) are more sensitive, general anesthesia may be necessary in 
certain cases.
• Careful fly protection, wound management and regular checks must be part of 
the long-term management of any sarcoid-affected horse.
• Spontaneous remission is reported but rare, the decision to delay treatment 
based on a possible spontaneous remission is discouraged.
6.2 Benign neglect
As previously discussed, a proper treatment should follow the diagnosis of 
equine sarcoid, but in some cases benign neglect may be an option. Horses may pres-
ent with such extensive lesions that any treatment method would be impractical. In 
other patients, the sarcoids may be small enough to render the procedure too expen-
sive. Clinicians should opt for benign neglect with caution, both patient welfare and 
the lesions should be strictly monitored as sarcoids can progress. Furthermore, their 
presence may contribute to spread to other sites and horses [3, 55].
Figure 12. 
Periorbital sarcoid, eyelid function must be preserved when treating these lesions.
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6.3 Surgical methods
• Sharp surgical excision: this technique is often appealing to practitioners and, 
in some cases, easy and successful but carries rates of recurrence as high as 
70%, with recurrences occurring mostly within few months or even during the 
healing process and being much more aggressive (commonly fibroblastic) than 
the original sarcoid [2, 3, 46]. Wide excision is necessary to reduce the risk of 
recurrence, but it is not always practical or feasible and a safe margin is impos-
sible to define. The principle of smart surgery should be applied to minimize 
cell contamination during surgery. Protecting the tumor with adhesive dress-
ings before surgery reduces contamination and in case of recurrence another 
therapeutic method or combined treatments are indicated [3, 55]. Occult and 
verrucose sarcoids can be effectively removed with wide margins, nodules in 
the eyelids are invasive thus very dangerous, whereas other nodular lesions 
may respond better. However, the prognosis is usually very guarded when 
using surgery alone [55].
• Cryosurgery: this method causes tumor necrosis and is commonly used but has 
the same limitations as surgical excision. It can be used successfully on superfi-
cial lesions but restriction of blood flow, a defined safety margin and adjuvant 
chemotherapy (intralesional or topical) during the procedure can improve 
outcome. It can be repeated if necessary until the tumor is completely removed 
but the ability of the patient to resist the cold can be a limitation [3, 55, 69].
• Hyperthermia/radiofrequency hyperthermia: the tumor, being more sensitive 
to temperature than normal tissue, is heated for 30 s to 50°C weekly for up to 
5 weeks. Very few cases are reported using this technique that is not generally 
recognized in equine practice [55].
• Surgical electrocautery: this method was recently reported with a high rate 
of success, its advantages are the minimal bleeding into the wound site with 
a reduced risk of tumor cell contamination and usually limited scarring. 
Electrocautery is one of the few options for sarcoids on the ear pinna [3, 55, 70].
• Laser surgery: surgical ablation with CO2-YAG laser or diode laser devices is 
reported with success rates as high as more than 80%. When accurately used, 
this method is associated with the ability to sterilize the wound, no bleeding 
and avoids seeding tumor cells during the procedure. CO2 lasers cause less 
thermal injury than diode ones. Primary closure may be possible, but a high 
rate of wound dehiscence and slow healing are disadvantages. Careful selection 
of the lesion is important: recurrence is most likely in verrucose sarcoids with 
poorly defined margins, whereas localized pinnal sarcoids and fibroblastic 
type 1a tumors around the eye may respond well [3, 55, 71, 72].
• Ligation: this method can be used only on pedunculated sarcoids where no 
tumor extensions are present in the pedicle below the ligature. This means 
that it is suitable for nodular type A1 and B1 or fibroblastic type 1a sarcoids, or 
any sarcoid where an artificial tumor-free pedicle can be created. The pedicle 
is ligated with castration/elastration bands, it works better if several bands 
can be placed and if adjunctive intralesional or chemotherapy are combined. 
The use of plastic ties or suture material that cut the lesion and partial liga-
tion should be avoided as it carries a poorer prognosis and is associated with 
exacerbation or recurrence [3, 55].
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6.4 Chemotherapy
Different chemotherapeutic agents and compounds can be used to treat sarcoids, 
usually they are topically or intralesionally administered with little or no systemic 
effects [55]. Systemic doxorubicin was used only in one study, but limitations and 
constraints to its use reserve this treatment only to very extensive or wide-spread 
lesions referred to specialist centers [3, 73].
• Topical and intralesional 5-fluorouracil: this cytotoxic and antimitotic agent 
can be topically applied as 5% ointment with a twice daily protocol over a few 
weeks. It is usually successful on small occult and verrucose lesions, or to con-
trol large areas that cannot be treated with other modalities. During treatment 
an inflammatory reaction can be marked but usually minimal scarring follows. 
It can also be combined with surgery [3, 55, 74]. The intralesional injection 
of 5-fluorouracil at the dose of 50 mg/cm3 every 2 weeks for up to 7 weeks is 
reported with a successful rate of 61.5%, sarcoids larger than 13.5 cm3 had a 
poorer prognosis compared with smaller lesions [75].
• Topical imiquimod: this agent is an immune response modifier with potent 
antiviral and antitumor activity and is used to treat human genital warts. 
The reported protocol for equine sarcoid is to apply the cream three times a 
week for 16–32 weeks. The treatment is usually associated with inflammation, 
alopecia and depigmentation. Administration of oral phenylbutazone can be 
helpful in some cases to control the discomfort [55, 70, 76].
• Topical AW5: it is a cream containing heavy metal salts, fluorouracil, thio-
uracil and steroid. Its use is restricted to veterinarians only, protocols include 
repeated applications but it can be contraindicated in some cases such as 
around the eye or other structures (facial nerve) that can be damaged. The 
reported success rate is around 74% depending on lesion and previous treat-
ment history [3, 52, 55].
• Topical acyclovir: topical 5% acyclovir cream has been used to treat sarcoids 
with some benefits reported in one study [77]. A subsequent retrospective 
case-series and a double-blinded placebo-controlled trial resulted in no 
advantages from this agent compared to other treatments or placebo [70, 78]. 
The cream is used without prescription for human herpes virus infection and 
this may be attractive for owners that desire to treat horses without looking for 
veterinary advice with deleterious effects [3].
• Silver nitrate: silver nitrate caustic pencil is an old-fashioned treatment that can 
be applied to very localized small lesions [55].
• Intralesional cisplatin: this chemotherapeutic agent has been used in several 
studies in the form of injectable solution, emulsion and of biodegradable beads. 
Resolution rates are up to 93% in sarcoids less than 5 cm in diameter, larger 
lesions can be cured combining surgical debulking and intralesional cisplatin 
[3, 55]. A general protocol includes repeated injections of cisplatin oily emul-
sion at the dose of 1 mg/cm3 every 2 weeks for four times but intervals may 
change upon patient needs. The material does not diffuse more than 5 mm in 
tissues so several injections every 6 mm–1 cm of tumor and margin of normal 
tissue are necessary. The aqueous solution has a clearance of minutes whereas 
the medical-grade sesame seed oil emulsion has the advantage of a lower 
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concentration and a slower release. Due to the high toxicity, self-protection 
measures must be strictly respected when handling cisplatin [3, 55, 79]. The 
use of biodegradable beads containing cisplatin is also reported with or without 
surgical debulking, the latter is usually necessary in tumors larger than 1.5 cm 
in diameter. Beads are placed at 1–1.5 cm intervals along the wound or tumor 
margins [3, 55, 70, 80].
• Bleomycin: bleomycin is a glycopeptide antibiotic with antineoplastic activity, 
it has been used to treat sarcoids intralesionally and with the use of electro-
chemotherapy. Recently the topical use on occult and verrucose sarcoids of 
an ultradeformable liposomal preparation of bleomycin, alone or following 
5-fluorouracil or tazarotene application, has shown good efficacy with the 
absence of pain and inflammation as an advantage [3, 81].
• Electrochemotherapy: electrochemotherapy is based on the use of electrically 
induced increases in cell membrane permeability to increase the effects of 
cytotoxic agents such as cisplatin, carboplatin, and bleomycin. It requires 
repeated general anesthesia, up to 8 treatments, and specialist equipment [3, 
79, 82, 83].
6.5 Photodynamic therapy
This method is based on photosensitization of tumor cells with a topical or 
intralesional photosensitizer (e.g. hypericin or 5-aminolevulinic acid and deriva-
tives) followed by the application of a specific light wavelength emitted by a proper 
light source, for a defined time (minutes). The mechanism is complex and takes 
advantage of the production of reactive oxygen species that kill sensitized cells, so 
it is very localized. The literature on its use on sarcoids is limited but significant 
benefits are reported, with or without surgical debulking [3, 84–88].
6.6 Immunotherapy
Since the involvement of BPV infection, much research is being focused on 
immunologic methods but without practical results so far. Moreover, horses do not 
seroconvert for BPV and vaccination does not prevent sarcoid development [3].
• Spontaneous remission: it is generally reported as rare, however, a recent study 
just reported a high proportion of spontaneous remission in a population 
of Franches-Montagnes horses in Switzerland [53]. The mechanism is not 
clear yet and antibodies have been detected only in donkeys [5]. Long-term 
immunity appear to occur in horses with sarcoids that undergo spontaneous 
remission [3].
• Immunomodulation: the use of intralesional injection of the bacillus Calmette-
Guérin (BCG) is reported in different studies with high success rates, espe-
cially around the eye. Sarcoids on the distal limbs respond less or may even 
exacerbate [3, 69, 89, 90]. This method gives best results on nodular and 
fibroblastic sarcoids but may be associated with anaphylaxis, especially when 
repeated injections are performed [55, 90].
• Vaccines: attempts to stimulate sarcoid regression or potential preventive effects 
through autogenous and BPV-1 L1virus-like particles vaccines have been made 
but further studies are needed [3, 91].
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• Autoinoculation/autografting: the inoculation of sarcoid tissue is reported in two 
studies, but doubts are raised about this method due to the risk of complica-
tions and the fact that it is not described for other cancers in any species [3, 92].
• Hemotherapy: no literature is available describing the effectiveness of this method. 
However, it is widely used in Central America and consists of withdrawal of 
venous blood and its intramuscular injection with anecdotal success [3].
6.7 Gene therapy
Mediator-governed therapy and genetic manipulation are under research but no 
practical treatment for the equine sarcoid has been reported yet [3, 27].
6.8 Radiotherapy
Facilities and special equipment are required for radiation therapy, which 
contribute to its high costs and limited availability. Different techniques exist:
• Teletherapy: it is expected to be effective, but few reports exist [3, 93].
• Brachytherapy: using radioactive radon, iridium and gold isotopes, it has 
become the gold standard for sarcoids, especially periorbital lesions [3, 93–96].
• Plesiotherapy: this surface brachytherapy method uses beta radiation from 
strontium90 and is reported on small superficial sarcoids [3, 93].
6.9 Adjunctive therapy
To remove secondary epidermal changes in sarcoid tumors, tazarotene can be 
used as adjunctive treatment. It is a retinoid 0.1% gel commonly used in human 
medicine for the management of keratinization disorders [3].
6.10 Phytotherapy
• Viscus album austriacus: the use of the injectable extract of the white mistletoe 
plant is reported to have immunomodulating effects in humans and was 
used in one double-blinded placebo-controlled trial in horses with sarcoids. 
Repeated subcutaneous injections for 15 weeks provided a positive outcome 
compared to placebo [3, 97].
• Sanguinaria canadensis/zinc chloride: commercially available compounds 
containing bloodroot (S. canadensis) and zinc chloride are anecdotally used for 
the treatment of equine sarcoids. Although high rates of success are reported 
on the internet, the use of this material by owners without veterinary advice 
carries risks. The use of this product on horses is not supported by scientific 
literature and dangerous toxicity in humans is reported [3].
6.11 Other remedies
Several ‘natural’ or herbal or homeopathic remedies are often used to treat 
sarcoids, usually with a delay in proper treatment and a risk of interference causing 
exacerbation of the tumor. Caution should be used considering the use of any mate-
rial suggested to treat every condition in every species [3].
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7. Sarcoids in other equids
Sarcoid tumors are reported also in animals other than horses. Donkeys, mules, 
and zebras can be affected, but reports of sarcoid tumors associated to BPV infec-
tion exist also in cats, giraffes, sable antelopes, and captive tapirs [98–104].
As far as equids are concerned, the reported prevalence of sarcoids in zebras is 
25–53%, whereas incidence in UK donkeys is 0.6 per 100 animal years with appar-
ent increased risk for young males [5, 105, 106]. The equine sarcoid is reported as 
the most common tumor in donkeys and presence of sarcoids among these equids 
and zebras is sometimes reported as outbreaks [105–109].
Diagnostic and treatment methods are the same as for horses, one study reports 
the use of surgical excision, intralesional 5-fluorouracil, allogenous vaccine or 
5-fluorouracil in combination with autogenous vaccine in zebras [98, 110].
8. Conclusions
The equine sarcoid is a locally invasive skin neoplasm commonly encountered 
in practice. It has different clinical presentations, and early diagnosis with prompt 
treatment can improve the prognosis, but their importance is often underesti-
mated. Several treatment options are available with variability in lesion and patient 
response. Spontaneous regression is rare, recurrence is common, and exacerbation 
is a possible complication, especially when a wrong therapy is attempted. Sarcoid-
affected animals can never be considered free of the disease and horse owners must 
be correctly informed about the features and behavior of this tumor.
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